Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer

被引：0
作者：
Bundred, James [1 ]
Lal, Nikhil [1 ]
Chan, Dedrick K. H. [2 ]
Buczacki, Simon J. A. [1 ]
机构：
[1] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England
[2] Yong Loo Lin Sch Med, NUS Ctr Canc Res, Singapore City, Singapore
来源：
BRITISH JOURNAL OF CANCER | 2025年
关键词：
COMPLETE MESOCOLIC EXCISION; COLORECTAL-CANCER; STAGE MIGRATION; SURVIVAL; SURGERY; NUMBER; RESECTION; OUTCOMES; QUALITY; COUNTS;
D O I：
10.1038/s41416-025-02949-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BackgroundWe interrogated two large national databases to explore the underlying mechanisms and institutional effects of the known association of enhanced survival with a higher lymph node yield (LNY) in non-metastatic colon cancer.MethodClinical and pathological data for stage I-III colon adenocarcinomas were extracted from the CORECT-R (England, 2010-2020) and SEER database (USA, 2000-2020). A lymph node (LN) cut-off for the lack of clinically significant increase in nodal positivity was identified. A multivariable Cox-regression model was developed to study the effect of LNY on overall survival. Furthermore, institutional variations in LNY and their impact on survival were explored.ResultsPatients were retrospectively included from the CORECT-R (n = 84,116) and SEER (n = 287,974) databases. No significant increase in nodal positivity was noted after a LN cut-off of 9. However, improved survival was noted in node-negative and node-positive cancers beyond this cut-off. A 1% risk-reduction concerning overall survival was reported for every node counted. We identified ten outlying institutions across England with an observed LNY greater or less than the expected, with no impact on overall survival.DiscussionsWe advocate incorporating LNY into patient and clinician discussions as a surrogate marker of tumour biology and prognosis rather than using LNY as a quality indicator.
引用
收藏
页码：643 / 651
页数：9
相关论文
共 39 条
  • [1] Rawla P., Sunkara T., Barsouk A., Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors, Prz Gastroenterol, 14, pp. 89-103, (2019)
  • [2] Gunderson L.L., Jessup J.M., Sargent D.J., Greene F.L., Stewart A.K., Revised TN categorization for colon cancer based on national survival outcomes data, J Clin Oncol, 28, pp. 264-271, (2010)
  • [3] Parsons H.M., Tuttle T.M., Kuntz K.M., Begun J.W., McGovern P.M., Virnig B.A., Association between lymph node evaluation for colon cancer and node positivity over the past 20 years, JAMA, 306, pp. 1089-1097, (2011)
  • [4] Lal N., Chan D.K.H., Ng M.E., Vermeulen L., Buczacki S.J.A., Primary tumour immune response and lymph node yields in colon cancer, Br J Cancer, 126, pp. 1178-1185, (2022)
  • [5] Bui L., Rempel E., Reeson D., Simunovic M., Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study, J Surg Oncol, 93, pp. 439-445, (2006)
  • [6] Halsted W.S.I., The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894, Ann Surg, 20, pp. 497-555, (1894)
  • [7] Fisher B., Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture, Cancer Res, 40, pp. 3863-3874, (1980)
  • [8] Feinstein A.R., Sosin D.M., Wells C.K., The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer, N Engl J Med, 312, pp. 1604-1608, (1985)
  • [9] Derwinger K., Carlsson G., Gustavsson B., Stage migration in colorectal cancer related to improved lymph node assessment, Eur J Surg Oncol, 33, pp. 849-853, (2007)
  • [10] Chang G.J., Rodriguez-Bigas M.A., Skibber J.M., Moyer V.A., Lymph node evaluation and survival after curative resection of colon cancer: systematic review, J Natl Cancer Inst, 99, pp. 433-441, (2007)
1234